Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome

Journal of Infection and Public Health

Volumn 9, Issue 3, 2016, Pages 231-235

  Corti, Davide ^a   Passini, Nadia ^a   Lanzavecchia, Antonio ^b,c   Zambon, Maria ^d  

^a Humabs BioMed SA ^*  (Switzerland)

^b INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Switzerland)

^c ETH ZURICH   (Switzerland)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN MONOCLONAL ANTIBODY; HUMAN MONOCLONAL ANTIBODY LCA60; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; VIRUS ANTIBODY;

ANTIBODY ISOLATION; ARTICLE; CORONAVIRIDAE INFECTION; DRUG ISOLATION; HUMAN; MEMORY CELL; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; RESPIRATORY FAILURE; RESPIRATORY TRACT DISEASE; VIRAL RESPIRATORY TRACT INFECTION; VIRUS NEUTRALIZATION; ANIMAL; BIOTECHNOLOGY; CHO CELL LINE; CORONAVIRUS INFECTIONS; CRICETULUS; IMMUNOTHERAPY; ISOLATION AND PURIFICATION; PHARMACEUTICS; PROCEDURES; TIME FACTOR;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; BIOTECHNOLOGY; CHO CELLS; CORONAVIRUS INFECTIONS; CRICETULUS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; TECHNOLOGY, PHARMACEUTICAL; TIME FACTORS;

EID: 84963799673     PISSN: 18760341     EISSN: 1876035X     Source Type: Journal    
DOI: 10.1016/j.jiph.2016.04.003     Document Type: Article

References (11)

1. Arabi Y.M., Arifi A.A., Balkhy H.H., Najm H., Aldawood A.S., Ghabashi A., et al. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann Intern Med 2014, 160:389-397. 10.7326/M13-2486.
2. Haagmans B.L., Dhahiry Al S.H.S., Reusken C.B.E.M., Raj V.S., Galiano M., Myers R., et al. Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation. Lancet Infect Dis 2014, 14:140-145. 10.1016/S1473-3099(13)70690-X.
3. Zaki A.M., van Boheemen S., Bestebroer T.M., Osterhaus A.D.M.E., Fouchier R.A.M. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012, 367:1814-1820. 10.1056/NEJMoa1211721.
4. Bermingham A., Chand M.A., Brown C.S., Aarons E., Tong C., Langrish C., et al. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Euro Surveill 2012, 17:20290.
5. Assiri A., McGeer A., Perl T.M., Price C.S., Al Rabeeah A.A., Cummings D.A.T., et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 2013, 10.1056/NEJMoa1306742.
6. Mair-Jenkins J., Saavedra-Campos M., Baillie J.K., Cleary P., Khaw F.-M., Lim W.S., et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015, 211:80-90. 10.1093/infdis/jiu396.
7. Traggiai E., Becker S., Subbarao K., Kolesnikova L., Uematsu Y., Gismondo M.R., et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 2004, 10:871-875. 10.1038/nm1080.
8. Corti D., Lanzavecchia A. Efficient methods to isolate human monoclonal antibodies from memory B cells and plasma cells. Microbiol Spectr 2014, 2:129-139. 10.1128/microbiolspec.AID-0018-2014.
9. Corti D., Zhao J., Pedotti M., Simonelli L., Agnihothram S., Fett C., et al. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. Proc Natl Acad Sci U S A 2015, 112:10473-10478. 10.1073/pnas.1510199112.
10. Burton D.R., Saphire E.O. Swift antibodies to counter emerging viruses. Proc Natl Acad Sci U S A 2015, 112:10082-10083. 10.1073/pnas.1513050112.
11. Borio L., Cox E., Lurie N. Combating emerging threats - accelerating the availability of medical therapies. N Engl J Med 2015, 373:993-995. 10.1056/NEJMp1508708.